Group 1 - The core viewpoint of the article highlights the strong market response to the public offering of Zhuozheng Medical, with a total subscription amount reaching HKD 35.3 billion, indicating an oversubscription of approximately 1,118 times [1] - Zhuozheng Medical plans to globally offer 4.75 million shares, with 10% allocated for public sale in Hong Kong, and the offering price set between HKD 57.7 and HKD 66.6 [1] - The company aims to establish a one-stop family health service center, modeled after Costco, leveraging a membership system, high cost-performance, and selected service categories to create a positive growth cycle [1] Group 2 - Zhuozheng Medical does not rely on medical insurance or marketing, instead focusing on a high-value membership ecosystem and AI empowerment to lead the industry with counter-cyclical growth [1] - The company boasts a prestigious shareholder lineup led by Tencent, with participation from He Xiaopeng and several AI enterprises affiliated with Tencent [1]

Core Viewpoint - The Hong Kong stock market is experiencing a strong start in 2026, with multiple companies successfully listing, and over 300 more in the pipeline, particularly in technology, biomedicine, and consumer sectors, driven by favorable economic conditions [1] Group 1: Company Overview -卓正医疗控股有限公司 is positioned as a new force in health service consumption, focusing on high-end health services with a patient-centric approach [2] - The company aims to create a one-stop family health service center by integrating a membership model inspired by Costco, enhancing patient experience through high-quality service [2][3] Group 2: Service Model and Operations -卓正医疗 offers integrated online and offline services, covering various specialties such as pediatrics, dentistry, and internal medicine, which enhances patient satisfaction and facilitates cross-specialty referrals [2][3] - The company operates 19 multi-specialty medical service institutions across China, focusing on high-quality professional medical teams, with an average of 15 years of clinical experience among its 387 full-time doctors [3] Group 3: Patient Growth and Loyalty -卓正医疗 has seen a significant increase in patient visits, with total patient consultations rising from 162,400 in 2022 to 242,500 in 2024, and further increasing to 212,200 in the first eight months of 2025 [4] - The company has achieved a high patient loyalty rate, with repeat visit rates increasing from 75.7% in 2022 to 82.7% in the first eight months of 2025 [4] Group 4: Financial Performance -卓正医疗's revenue grew from 473 million yuan in 2022 to 959 million yuan in 2024, with a compound annual growth rate of 42.3%, demonstrating robust growth without relying on insurance or large-scale marketing [5] - The company's net promoter score (NPS) has consistently increased, indicating strong customer satisfaction and low customer acquisition costs, with sales expenses as a percentage of total revenue significantly below the industry average [5] Group 5: Market Position and Future Outlook -卓正医疗 has established itself as the third-largest private high-end comprehensive medical service provider in China by total revenue as of 2024, leading in key metrics such as the number of covered cities and paid patient visits [7] - The company is well-positioned to capitalize on the growing demand for high-quality, personalized medical services among China's affluent population, which is projected to grow from 104.1 million in 2020 to 123.1 million in 2024 [8]